Functionalized theranostic agents
have the potential to be an effective
tool for targeting tumor cells with an effective response in cancer
imaging and therapy. Particularly, near-infrared (NIR) light is extremely
advantageous and can penetrate deeply into biological tissues with
minimum attenuation and photodamage to cells. The major impediment
to the translation of research into clinical applications is toxicity
and long-term body retention. Designing renal clearable and theranostic
qualities in a single nanoplatform remains the biggest challenge.
Especially, nanomaterials have optical absorption in the second biowindow
(NIR-II) with deep penetration and less tissue scattering. Photothermal
therapy (PTT), which uses hyperthermia produced by photothermal agents
(PTAs) that convert light irradiation to ablate tumors, has received
great attention due to its noninvasiveness. Herein, we developed an
NIR-II-responsive ultrasmall polypyrrole (PPy)-based theranostic agent
conjugated with TAT peptide that has a unique nuclear-targeting property
that allows for efficient nuclear-targeted photothermal ablation and
immunogenic cell death (ICD). Furthermore, PPy decorated with hyaluronic
acid (HA)-loaded toll-like receptor 7/8 immune-activating drug resiquimod
(R848), a synthetic agonist for the maturation of dendritic cells.
Therefore, the prepared nanocomposite leads to effective tumor cell
nuclear ablation, together with a photothermal immune response and
renal clearance. This strategy may provide another avenue for highly
efficient cancer theranostic nanovaccines.